# OnCo record keynote-006 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-006/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-006", "NCT01866319" ;
  schema:name "KEYNOTE-006"@en ;
  schema:description "The trial that made PD-1 blockade the first choice over the older CTLA-4 drug, with a third of patients alive at ten years."@en ;
  schema:url <https://onco.cc/trials/keynote-006/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01866319>, <https://www.annalsofoncology.org/article/S0923-7534(24)03910-3/fulltext> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2013-08-28" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/caroline-robert/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/> .